|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
THE ARAB DRUG MANUFACTURING CO.
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Gonorrhea |
|
Infection, ear, middle |
|
Infection, genital tract |
|
Infection, lower respiratory tract |
|
Infection, sinus |
|
Infection, skin and skin structure |
|
Infection, upper respiratory tract |
|
Infection, urinary tract |
|
Pharyngitis |
|
Pneumonia |
|
Tonsillitis |
|
Ulcer, H. pylori associated |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
acute generalized exanthematous pustulosis (AGEP) |
|
agranulocytosis |
|
anaphylactic shock |
|
anaphylactoid reactions |
|
anemia |
|
anorexia |
|
bullous rash |
|
candidiasis |
|
cholestasis |
|
colitis |
|
crystalluria |
|
dental fluorosis |
|
diarrhea |
|
dizziness |
|
dysphagia |
|
elevated hepatic enzymes |
|
eosinophilia |
|
erythema multiforme |
|
esophagitis |
|
exfoliative dermatitis |
|
gastritis |
|
headache |
|
hemolysis |
|
hemolytic anemia |
|
hepatitis |
|
insomnia |
|
interstitial nephritis |
|
jaundice |
|
leukopenia |
|
maculopapular rash |
|
nausea/vomiting |
|
nephrotic syndrome |
|
neutropenia |
|
odynophagia |
|
platelet dysfunction |
|
prolonged bleeding time |
|
pseudomembranous colitis |
|
purpura |
|
rash (unspecified) |
|
seizures |
|
serum sickness |
|
Stevens-Johnson syndrome |
|
superinfection |
|
thrombocytopenia |
|
tooth discoloration |
|
toxic epidermal necrolysis |
|
urticaria |
|
vasculitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
asthma |
|
breast-feeding |
|
carbapenem hypersensitivity |
|
cephalosporin hypersensitivity |
|
colitis |
|
diabetes mellitus |
|
dialysis |
|
diarrhea |
|
eczema |
|
GI disease |
|
infants |
|
infection |
|
leukemia |
|
mononucleosis |
|
neonates |
|
phenylketonuria |
|
pregnancy |
|
renal failure |
|
renal impairment |
|
syphilis |
|
|
ADULT DOSE:
|
|
Antibacterial-
Ear, nose, and throat infections: Mild or moderate-Oral, 500 mg every twelve hours or 250 mg every eight hours. Severe-Oral, 875 mg every twelve hours or 500 mg every eight hours.
Lower respiratory tract infections: Mild, moderate, or severe-Oral, 875 mg every twelve hours or 500 mg every eight hours.
Skin or skin structure infections: Mild or moderate-Oral, 500 mg every twelve hours or 250 mg every eight hours. Severe-Oral, 875 mg every twelve hours or 500 mg every eight hours.
Genitourinary tract infections: Mild or moderate-Oral, 500 mg every twelve hours or 250 mg every eight hours. Severe-Oral, 875 mg every twelve hours or 500 mg every eight hours.
Gonorrhea, acute uncomplicated (anogenital and urethral infections): Oral, 3 grams as a single dose.
Endocarditis, bacterial (prophylaxis): Oral, 3 grams one hour before the procedure, then 1.5 grams six hours after the initial dose.
Duodenal ulcer, Helicobacter pylori -associated : Triple antibiotic therapy: Oral, 1000 mg amoxicillin with 500 mg clarithromycin and 30 mg lansoprazole two times a day at twelve-hour intervals for fourteen days. Dual antibiotic therapy: Oral, 1000 mg amoxicillin with 30 mg lansoprazole three times a day at eight-hour intervals for fourteen days.
[Chlamydia, treatment in pregnant women] : Oral, 500 mg every eight hours for seven to ten days.
[Gastritis, Helicobacter pylori] or
[Ulcer, peptic, Helicobacter pylori] : Oral, 500 mg four times a day; or 750 mg three times a day.
[Lyme disease] : Oral, 250 to 500 mg three or four times a day for three to four weeks. Duration of therapy is based on clinical response. Treatment failures have occurred and retreatment may be necessary.
Patients with severe renal function impairment require an adjustment in dosage as follows :
Patients with a glomerular filtration rate of 10-30 mL per minute-Oral, 500 mg or 250 mg every twelve hours, depending on the severity of the infection.
Patients with a glomerular filtration rate of < 10 mL per minute-Oral, 500 mg or 250 mg every twenty-four hours, depending on the severity of the infection.
Patients on hemodialysis-Oral, 500 mg or 250 mg every twenty-four hours, depending on the severity of the infection. An additional dose should be administered both during and at the end of the dialysis session.
Note: Patients with severe renal function impairment (glomerular filtration rate of < 30 mL per minute) should not receive the 875-mg tablet. |
|
MAXIMUM ADULT DOSE:
|
|
4.5 grams a day.
|
|
PEDIATRIC DOSE:
|
|
Antibacterial-
Gonorrhea, endocervical and urethral, uncomplicated: Oral, 50 mg per kg of body weight and 25 mg of probenecid per kg of body weight simultaneously as a single dose in prepubertal children. However, probenecid is not recommended in children under 2 years of age.
Duodenal ulcer, Helicobactor pylori -associated : Safety and efficacy have not been established for pediatric or adolescent patients.
[Lyme disease] : Oral, 6.7 to 13.3 mg per kg of body weight every eight hours for ten to thirty days. Duration of therapy is based on clinical response. Treatment failures have occurred and retreatment may be necessary.
For all other indications: Infants and children up to 40 kg of body weight, see Amoxicillin for Oral Suspension USP .
Children 40 kg of body weight and over-See Usual adult dose. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|